Adult Dosing
Metastatic colorectal cancer
- 4 mg/kg IV infusion over 1 hr q2 wks
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Therapy is restricted in patients with severe hemorrhage since severe and sometimes fatal cases, including GI bleeding, have been reported in patients receiving ziv-aflibercept [FDA Black Box warning]
- Suspend therapy in patients experiencing GI perforation [FDA Black Box warning]
- Therapy should be discontinued in patients with compromised wound healing. Discontinue 4 weeks before and 4 weeks after major surgery and when wound fully healed [FDA Black Box warning]
- Therapy should be discontinued if fistula formation involving gastrointestinal and non-gastrointestinal sites occur
- Blood pressure should be monitored and maintained during therapy. Temporarily discontinue therapy if uncontrolled hypertension and hypertensive crisis occur
- Discontinue therapy in patients who experience arterial thromboembolic events (ATE)
- Urine protein should be monitored during therapy. Suspend if proteinuria
2 gms/24 hrs. Therapy should be discontinued if nephrotic syndrome or thrombotic microangiopathy (TMA) develops - Therapy may cause neutropenic complications. Delay administration until neutrophil count is 1.5 x 109/L
- Incidence of severe diarrhea and dehydration is increased with therapy. Elderly patients should be monitored closely during therapy
- Suspend therapy if Reversible Posterior Leukoencephalopathy Syndrome (RPLS) occur
Cautions: Use cautiously in
- Proteinuria
- History of thromboembolism
- Patients >65 years of age
Pregnancy Category:C
Breastfeeding: Safety unknown. According to manufacturer a decision should be made for discontinuing nursing or discontinue the drug taking into account the importance of the drug to the mother.
